

**Supplementary Table 3.** Logistic regression analysis of best treatment response

Characteristics	Unmatched cohort		After IPTW		After PSM	
	OR (95% CI)	P-value	OR (95% CI)	P-value	OR (95% CI)	P-value
TARE vs. TKI	11.7 (5.64–24.1)	<0.001	8.05 (3.35–19.3)	<0.001	7.41 (3.09–17.8)	<0.001
Female vs. Male	1.59 (0.75–3.38)	0.23	1.33 (0.58–3.06)	0.51	0.79 (0.26–2.44)	0.68
ECOG PS						
0	[Reference]		[Reference]		[Reference]	
1	0.40 (0.23–0.71)	0.002	0.47 (0.24–0.91)	0.03	0.53 (0.25–1.13)	0.10
2	0.32 (0.03–3.13)	0.32	0.38 (0.04–3.91)	0.41	NA	NA
Child–Pugh score						
5	[Reference]		[Reference]		[Reference]	
6	0.33 (0.15–0.73)	0.007	0.57 (0.23–1.43)	0.23	0.61 (0.23–1.61)	0.31
7	0.19 (0.04–0.87)	0.03	0.11 (0.02–0.60)	0.01	0.52 (0.10–2.73)	0.44
Hepatic encephalopathy	0.93 (0.35–2.50)	0.89	0.71 (0.24–2.12)	0.54	0.28 (0.03–2.39)	0.24
Ascites	0.49 (0.22–1.07)	0.08	0.36 (0.15–0.88)	0.03	0.42 (0.13–1.37)	0.15
Tumor type						
Well-defined (nodular)	[Reference]		[Reference]		[Reference]	
Ill-defined (infiltrative)	0.96 (0.56–1.66)	0.88	1.23 (0.65–2.33)	0.52	1.57 (0.74–3.35)	0.24
Tumor size, cm	0.96 (0.90–1.04)	0.31	0.98 (0.90–1.06)	0.53	0.97 (0.88–1.06)	0.50
Tumor number						
1	[Reference]		[Reference]		[Reference]	
2	0.88 (0.37–2.09)	0.78	1.09 (0.38–3.13)	0.87	1.29 (0.36–4.54)	0.70
≥3	0.25 (0.14–0.47)	<0.001	0.52 (0.26–1.06)	0.07	0.69 (0.30–1.55)	0.36
Tumor involvement						
Bilobar	[Reference]		[Reference]		[Reference]	
Unilobar (Right only)	1.86 (1.02–3.40)	0.045	1.05 (0.53–2.08)	0.89	1.11 (0.50–2.46)	0.79
Unilobar (Left only)	5.54 (2.14–14.3)	<0.001	6.74 (2.38–19.1)	<0.001	2.47 (0.66–9.25)	0.18
PVTT						
Vp1	[Reference]		[Reference]		[Reference]	
Vp2	0.91 (0.31–2.65)	0.86	0.76 (0.24–2.36)	0.63	1.73 (0.38–7.86)	0.48
Vp3	0.51 (0.18–1.47)	0.21	0.44 (0.15–1.33)	0.15	0.86 (0.20–3.76)	0.84
Albumin, g/dL	3.06 (1.58–5.90)	0.001	2.29 (1.10–4.73)	0.03	1.66 (0.71–3.90)	0.24
Bilirubin, mg/dL	0.31 (0.15–0.62)	0.001	0.29 (0.12–0.67)	0.004	0.24 (0.08–0.66)	0.006
PT, INR	0.82 (0.18–3.69)	0.80	0.76 (0.08–7.47)	0.81	0.17 (0.01–4.35)	0.29

A higher odds ratio indicates an increased likelihood of a higher object response rate.

CI, confidence interval; ECOG, Eastern Cooperative Oncology Group; IPTW, inverse probability of treatment weighting; NA, not applicable; OR, odds ratio; PS, performance status; PSM, propensity score matching; PT, prothrombin time; PVTT, portal vein tumor thrombosis; TARE, transarterial radioembolization; TKI, tyrosine kinase inhibitor.